Scarica l'app Stockscreener
148.17
0.39%
-0.58
Dopo l'orario di chiusura:
148.25
0.08
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Axsome Readies Alzheimer’s Drug Launch With Analyst Backing - Finimize
Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says - marketscreener.com
9,555 Shares in Axsome Therapeutics, Inc. $AXSM Purchased by WINTON GROUP Ltd - MarketBeat
How Investors Are Reacting To Axsome Therapeutics (AXSM) Revenue Surge Amid Wider Losses and Strategy Shift - Sahm
Axsome Therapeutics, Inc. $AXSM Shares Sold by HighVista Strategies LLC - MarketBeat
Invesco Ltd. Decreases Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Russell Investments Group Ltd. Boosts Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN
Hood River Capital Management LLC Acquires Shares of 371,104 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Jump Financial LLC Purchases 35,860 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Price-Driven Insight from (AXSM) for Rule-Based Strategy - news.stocktradersdaily.com
Kennedy Capital Management LLC Boosts Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Quantbot Technologies LP Grows Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Norges Bank Acquires New Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Schroder Investment Management Group Has $3.91 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Affinity Asset Advisors LLC Has $5.22 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) CEO Sells 10,558 Shares of Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $7,121,346.68 in Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) CEO Herriot Tabuteau Sells 20,163 Shares - MarketBeat
Can Axsome Therapeutics Inc. (19X) stock sustain breakout momentum2025 Performance Recap & Fast Entry High Yield Tips - Newser
Will Axsome Therapeutics Inc. stock outperform international peersCEO Change & Smart Money Movement Alerts - Newser
Is Axsome Therapeutics Inc. stock recession proof2025 AllTime Highs & Reliable Trade Execution Plans - Newser
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares By Investing.com - Investing.com South Africa
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares - Investing.com
Will Axsome Therapeutics Inc. (19X) stock outperform small cap peersEarnings Recap Summary & Growth Focused Investment Plans - Newser
Will Axsome Therapeutics Inc. stock outperform value stocksBull Run & Risk Controlled Swing Trade Alerts - Newser
Hsbc Holdings PLC Has $10.24 Million Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Is Axsome Therapeutics Inc. (19X) stock trading at attractive multiplesWeekly Trade Report & High Yield Equity Trading Tips - Newser
Rhumbline Advisers Has $6.45 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
What momentum indicators show for Axsome Therapeutics Inc. stockJuly 2025 Action & Risk Managed Trade Strategies - Newser
Is Axsome Therapeutics Inc. (19X) stock included in top ETFsTrade Exit Report & Low Drawdown Trading Strategies - Newser
Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Granite Investment Partners LLC Has $13.42 Million Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
How Axsome Therapeutics Inc. (19X) stock trades pre earningsJuly 2025 News Drivers & Weekly Chart Analysis and Trade Guides - Newser
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Swiss National Bank - MarketBeat
2 Under-the-Radar Stocks to Buy Heading Into 2026 - sharewise.com
Axsome Therapeutics (AXSM): Evaluating Valuation Following Recent Share Price Momentum and Pipeline Expansion - Yahoo Finance
2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
Axsome Therapeutics, Inc. $AXSM Shares Sold by Loomis Sayles & Co. L P - MarketBeat
Quadrature Capital Ltd Boosts Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
2,366 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Elevation Point Wealth Partners LLC - MarketBeat
Capital Fund Management S.A. Buys 47,738 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Jefferies Financial Group Inc. Makes New $261,000 Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
F m Investments LLC Takes $3.36 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Sold by PNC Financial Services Group Inc. - MarketBeat
Is Axsome Therapeutics Inc a good long term investmentHigh Dividend Yield Stocks & Free Turn Volatility To Profit - earlytimes.in
Axsome Therapeutics Stock (AXSM) Opinions on Recent Revenue Surge - Quiver Quantitative
Franklin Resources Inc. Acquires 51,995 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Atika Capital Management LLC Has $4.82 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome (AXSM) Q3 2025 Earnings Call Transcript - The Globe and Mail
Axsome Therapeutics, Inc. $AXSM Shares Sold by Rhenman & Partners Asset Management AB - MarketBeat
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):